The supporting information for the review article "Enhancing Cancer Immunotherapy: Nanotechnology-Mediated Immunotherapy Overcoming Immunosuppression" provides a comprehensive summary of nanomedicine approaches designed to overcome tumor immunosuppression. The article lists various nanocarriers and their modifications, such as porous hollow iron oxide nanoparticles (PHNPs), tumor-responsive therapeutic nanoparticles (TNPs), and supramolecular nanoparticles (S/NPs), which are loaded with different therapeutic agents like IL-12, α-TOS, doxorubicin, and siRNA. These nanocarriers are designed to modulate the tumor microenvironment, enhance immune responses, and improve the efficacy of cancer immunotherapy. The references section includes a detailed list of studies that support the effectiveness of these nanotechnology-based approaches in various cancer models, highlighting their potential in overcoming immunosuppression and enhancing anti-tumor immunity.The supporting information for the review article "Enhancing Cancer Immunotherapy: Nanotechnology-Mediated Immunotherapy Overcoming Immunosuppression" provides a comprehensive summary of nanomedicine approaches designed to overcome tumor immunosuppression. The article lists various nanocarriers and their modifications, such as porous hollow iron oxide nanoparticles (PHNPs), tumor-responsive therapeutic nanoparticles (TNPs), and supramolecular nanoparticles (S/NPs), which are loaded with different therapeutic agents like IL-12, α-TOS, doxorubicin, and siRNA. These nanocarriers are designed to modulate the tumor microenvironment, enhance immune responses, and improve the efficacy of cancer immunotherapy. The references section includes a detailed list of studies that support the effectiveness of these nanotechnology-based approaches in various cancer models, highlighting their potential in overcoming immunosuppression and enhancing anti-tumor immunity.